生长激素促分泌素的临床研究进展

摘要
图/表
参考文献(44)
相关文章 (1)

全文: PDF (0 KB) HTML (58 KB)
输出: BibTeX | EndNote (RIS)

摘要生长激素促分泌素（GHS）是一类可以促进生长激素释放的化合物的通称。生长激素促分泌素包括促生长激素分泌受体的激动剂和生长激素释放激素受体的激动剂。为了治疗或诊断由生长激素缺乏而导致的生长发育迟缓、胃肠功能障碍和身体成分指征改变，临床上已经开发了多种GHS，并进行了深入的机制和药理作用研究。本文将重点概述GHS 的研究历史、药理学研究结果以及随机临床试验数据。此外，笔者将着重介绍关于GHS 公开披露的全球临床试验进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孟广鹏
	李四军
	马浩宇
	徐苗
	刘爽
	高剑
	付晓平
	张兰

关键词 ：生长激素促分泌素, 阿拉莫林, 胃肠功能障碍, 生长发育迟缓

Abstract：Growth hormone secretagogue(GHS)is a generic term to describe compounds that increase growth hormone release.GHSs include agonists of the growth hormone secretagogue receptor,and agonists of the growth hormone-releasing hormone receptor.Several GHSs have been developed with a view to treating or diagnosing of growth hormone deficiency,which causes growth retardation,gastrointestinal dysfunction,and altered body composition,and in-depth studies on their mechanisms and pharmacology have been conducted.This review will focus on the history,pharmacological findings,and randomized clinical trial data of GHS.Furthermore,the author will highlight the publicly disclosed clinical trials regarding GHS.

Key words： Growth hormone secretagogue Anamorelin Gastrointestinal dysfunction Growth retardation

通讯作者: 张兰（1989-），女，甘肃武威人，博士，研究方向：药物研究与开发

作者简介: 孟广鹏（1990-），男，山西朔州人，博士，研究方向：药物研究与开发

引用本文:

孟广鹏；李四军；马浩宇；徐苗；刘爽；高剑；付晓平；张兰. 生长激素促分泌素的临床研究进展[J]. 中国当代医药, 2021, 28(25): 41-47转55.
MENG Guang-peng； LI Si-jun；MA Hao-yu；XU Miao；LIU Shuang；GAO Jian；FU Xiao-ping；ZHANG Lan. Clinical research progress of growth hormone secretagogues. 中国当代医药, 2021, 28(25): 41-47转55.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I25/41

[1]	Mathur N，Mehdi SF，Anipindi M，et al.Ghrelin as an Anti-Sepsis Peptide：Review[J].Front Immunol，2021，11：610 363.
[2]	Bowers C.GH releasing peptides-structure and kinetics[J].J Paediatric Endocrinol Metabol，1993，6（1）：21-32.
[3]	Bresciani E，Tamiazzo L，Torsello A，et al.Ghrelin control of GH secretion and feeding behaviour：the role of the GHSR1a receptor studied in vivo and in vitro using novel nonpeptide ligands[J].Eat Weight Disord，2008，13（3）：e67-74.
[4]	Howard AD，Feighner SD，Cully DF，et al.A receptor in pituitary and hypothalamus that functions in growth hormone release[J].Science，1996，273（5277）：974-977.
[5]	Argente J，García-Segura LM，Pozo J，et al.Growth hormonereleasing peptides：clinical and basic aspects[J].Horm Res，1996，46（4-5）：155-159.
[6]	Losa M，Schopohl J，Müller OA，et al.Stimulation of growth hormone secretion with human growth hormone releasing factors（GRF1-44，GRF1-40，GRF1-29）in normal subjects[J].Klin Wochenschr，1984，62（23）：1140-1143.
[7]	Prakash A，Goa KL.Sermorelin：a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency[J].Bio Drugs，1999，12（2）：139-157.
[8]	Neyzi O，Yordam N，Ocal G，et al.Growth response to growth hormone-releasing hormone（1-29）-NH2 compared with growth hormone[J].Acta Paediatr Suppl，1993，82（388）：16-21.
[9]	Thorner M，Rochiccioli P，Colle M，et al.Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy.Geref International Study Group[J].J Clin Endocrinol Metab，1996，81（3）：1189-1196.
[14]	Suckling K.Discontinued drugs in 2005：cardiovascular drugs[J].Expert Opin Investig Drugs，2006，15（11）：1299-1308.
[34]	Fink J，Schoenfeld BJ，Nakazato K.The role of hormones in muscle hypertrophy[J].Phys Sportsmed，2018，46（1）：129-134.
[10]	Carpino PA.Recent developments in ghrelin receptor（GHS-R1a）agonists and antagonists[J].Expert Opin Ther Pat，2002，12（11）：1599-1618.
[11]	Arvat E，di Vito L，Maccagno B，et al.Effects of GHRP-2 and hexarelin，two synthetic GH-releasing peptides，on GH，prolactin，ACTH and cortisol levels in man.Comparison with the effects of GHRH，TRH and hCRH[J].Peptides，1997，18（6）：885-891.
[12]	Imbimbo BP，Mant T，Edwards M，et al.Growth hormonereleasing activity of hexarelin in humans.A dose-response study[J].Eur J Clin Pharmacol，1994，46（5）：421-425.
[13]	Agbo E，Li MX，Wang YQ，et al.Hexarelin protects cardiac H9C2 cells from angiotensin Ⅱ-induced hypertrophy via the regulation of autophagy[J].Pharmazie，2019，74（8）：485-491.
[15]	Hansen BS，Raun K，Nielsen KK，et a l.Pharmacological characterisation of a new oral GH secretagogue，NN703[J].Eur J Endocrinol，1999，141（2）：180-189.
[16]	Zdravkovic M，Sgaard B，Ynddal L，et al.The pharmacokinetics，pharmacodynamics，safety and tolerability of a single dose of NN703，a novel orally active growth hormone secretagogue in healthy male volunteers[J].Growth Horm IGF Res，2000，10（4）：193-198.
[17]	Zdravkovic M，Christiansen T，Eliot L，et al.The pharmacokinetics，pharmacodynamics，safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects[J].Growth Horm IGF Res，2001，11（1）：41-48.
[18]	Svensson J，Monson JP，Vetter T，et al.Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency[J].Clin Endocrinol（Oxf），2003，58（5）：572-580.
[19]	Zdravkovic M，Olsen AK，Christiansen T，et al.A clinical study investigating the pharmacokinetic interaction between NN703（tabimorelin），a potential inhibitor of CYP3A4 activity，and midazolam，a CYP3A4 substrate[J].Eur J Clin Pharmacol，2003，58（10）：683-688.
[20]	Kageyama K，Sakihara S，Kameda W，et al.Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas[J].Endocr J，2018，65（10）：1049-1054.
[21]	Editorial A.Pralmorelin：GHRP 2，GPA 748，growth hormone-releasing peptide 2，KP-102 D，KP-102 LN，KP-102D，KP-102LN[J].Drugs R&D，2004，5（4）：236-239.
[36]	Reich N，Hlscher C.Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer′s and Parkinson′s Disease[J].Front Neurosci，2020，14：614 828.
[22]	Yuen KCJ，Llahana S，Miller BS.Adult growth hormone deficiency：clinical advances and approaches to improve adherence[J].Expert Rev Endocrinol Metab，2019，14（6）：419-436.
[23]	Piccoli F，Degen L，MacLean C，et al.Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects[J].J Clin Endocrinol Metab，2007，92（5）：1814-1820.
[24]	Garcia JM，Biller BMK，Korbonits M，et al.Macimorelin as a Diagnostic Test for Adult GH Deficiency[J].J Clin Endocrinol Metab，2018，103（8）：3083-3093.
[25]	James J，Mair S，Doll W，et al.The effects of ulimorelin，a ghrelin agonist，on liquid gastric emptying and colonic transit in humans[J].Neurogastroenterol Motil，2020，32（3）：e13784.
[26]	Sinha DK，Balasubramanian A，Tatem AJ，et al.Beyond the androgen receptor：the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males[J].Transl Androl Urol，2020，9（Suppl 2）：S149-S159.
[27]	Venkova K，Mann W，Nelson R，et al.Efficacy of ipamorelin，a novel ghrelin mimetic，in a rodent model of postoperative ileus[J].J Pharmacol Exp Ther，2009，329（3）：1110-1116.
[28]	Worm DJ，Els-Heindl S，Kellert M，et al.A stable metacarborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor[J].J Pept Sci，2018，24（10）：e3119.
[29]	Wargin W，Thomas H，Clohs L，et al.Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis：two randomized，double-blind studies and a binding profile study[J].Clin Drug Investig，2009，29（6）：409-418.
[30]	Vijayvargiya P，Camilleri M，Chedid V，et al.Effects of Promotility Agents on Gastric Emptying and Symptoms：A Systematic Review and Meta-analysis[J].Gastroenterology，2019，156（6）：1650-1660.
[31]	Camilleri M，Acosta A.Emerging treatments in Neurogastroenterology：relamorelin：a novel gastrocolokinetic synthetic ghrelin agonist[J].Neurogastroenterol Motil，2015，27（3）：324-332.
[32]	Camilleri M，Lembo A，McCallum R，et al.Overall safety of relamorelin in adults with diabetic gastroparesis：Analysis of phase 2a and 2b trial data[J].Aliment Pharmacol Ther，2020，51（11）：1139-1148.
[33]	Lembo A，Camilleri M，McCallum R，et al.Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis[J].Gastroenterology，2016，151（1）：87-96.e6.
[35]	Lee J，Kwon A，Chae HW，et al.Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats[J].Yonsei Med J，2018，59（10）：1174-1180.
[37]	Koutkia P，Canavan B，Breu J，et al.Growth hormone-releasing hormone in HIV-infected men with lipodystrophy：a randomized controlled trial[J].JAMA，2004，292（2）：210-218.
[38]	Falutz J，Allas S，Kotler D，et al.A placebo-controlled，doseranging study of a growth hormone releasing factor in HIVinfected patients with abdominal fat accumulation[J].AIDS，2005，19（12）：1279-1287.
[39]	Carpino PA，Lefker BA，Toler SM，et al.Discovery and biological characterization of capromorelin analogues with extended half-lives[J].Bioorg Med Chem Lett，2002，12（22）：3279-3282.
[40]	White HK，Petrie CD，Landschulz W，et al.Effects of an oral growth hormone secretagogue in older adults[J].J Clin Endocrinol Metab，2009，94（4）：1198-1206.
[41]	Katakami N，Uchino J，Yokoyama T，et al.Anamorelin（ONO-7643）for the treatment of patients with non-small cell lung cancer and cachexia：Results from a randomized，doubleblind，placebo-controlled，multicenter study of Japanese patients（ONO-7643-04）[J].Cancer，2018，124（3）：606-616.
[42]	Temel JS，Abernethy AP，Currow DC，et al.Anamorelin in patients with non-small-cell lung cancer and cachexia（ROMANA 1 and ROMANA 2）：results from two randomised，double-blind，phase 3 trials[J].Lancet Oncol，2016，17（4）：519-531.
[43]	Currow D，Temel JS，Abernethy A，et al.ROMANA 3：a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer（NSCLC）patients with cachexia[J].Ann Oncol，2017，28（8）：1949-1956.
[44]	Wakabayashi H，Arai H，Inui A.The regulatory approval of anamorelin for treatment of cachexia in patients with nonsmall cell lung cancer，gastric cancer，pancreatic cancer，and colorectal cancer in Japan：facts and numbers[J].J Cachexia Sarcopenia Muscle，2021，12（1）：14-16.